RALEIGH, NC, Feb. 14 /CNW/ -- DARA BioSciences, Inc. (Nasdaq: DARA) today
announced that the Company will present at the ROTH 20th Annual Growth Stock
Conference in Dana Point, CA on Tuesday, February 19, 2008 at 3:30pm Pacific.
Interested parties can access a live we b cast of the presentation at
www.darabiosciences.com. A replay of the presentation will be available at the
About DARA BioSciences, Inc.
DARA BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina -based
development-stage pharmaceutical company that acquires promising therapeutic
molecules and medical technologies directly or through investment in
established companies. DARA focuses its therapeutic development efforts on
small molecules from late preclinical development through phase 2 clinical
trials. DARA is developing a portfolio of therapeutic candidates for
europathic pain, metabolic diseases including type 2 diabetes, and
dermatological disorders. DARA has licensed promising drug development
candidates from Kirin Pharmaceuticals o f Japan, Bayer Pharmaceuticals
Corporation, Massachusetts General Hospital and Nuada LLC.
For more information please contact the Company at 919 -872-5578 or visit
our web site at www.darabiosciences.com.
All statements in this news release that are not historical are forward -
looking statements within the meaning of the Securities Exchange Act of 1934
as amended. Such forward -looking statements are subject to factors that could
cause actual results to differ materially for DARA from those projected. Those
factors include risks and uncertainties relating to the company's ability to
develop and bring new products to market as anticipated, the current
regulatory environment in which the company develops and sell s its products,
the market acceptance of those products, dependence on partner, successful
performance under collaborative and other commercial agreements, competition,
the strength of DARA's intellectual property, the intellectual property of
others and other risk factors identified in the documents DARA has filed, or
will file, with the Securities and Exchange Commission. Copies of DARA's
filings with the SEC may be obtained from the SEC Internet site at
http://www.sec.gov. DARA expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward - looking statements
contained herein to reflect any change in DARA's expectations with regard
thereto or any change in events, conditions, or circumstances on which any
such statements are based.
DARA BioSciences and the DARA logo are trademarks of DARA BioSciences,
For further information:
For further information: Lynn H. Morris, Sr. Manager, Investor Relations
& Corporate Operations, of DARA BioSciences, Inc., +1-919-872-5578 Web Site: